US FDA approve GSK's blood cancer treatment

Core Insights - The U.S. Food and Drug Administration has approved GSK's blood cancer drug, Blenrep, for use in combination with other treatments, indicating a significant regulatory milestone for the company [1] Company Summary - GSK is set to relaunch Blenrep following its FDA approval, which may enhance its market position in the oncology sector [1] Industry Summary - The approval of Blenrep reflects ongoing advancements in cancer treatment options, highlighting the competitive landscape within the pharmaceutical industry focused on oncology [1]